Summit Therapeutics, Inc. (SMMT)
12.72
-0.44
(-3.31%)
USD |
NASDAQ |
Aug 24, 16:00
12.72
0.00 (0.00%)
After-Hours: 20:00
Summit Therapeutics Debt to Equity Ratio : 0.0324 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0324 |
| March 31, 2026 | 0.0367 |
| December 31, 2025 | 0.0317 |
| September 30, 2025 | 0.0282 |
| June 30, 2025 | 0.0214 |
| March 31, 2025 | 0.0187 |
| December 31, 2024 | 0.0186 |
| September 30, 2024 | 0.0742 |
| June 30, 2024 | 0.5572 |
| March 31, 2024 | 2.477 |
| December 31, 2023 | 1.366 |
| September 30, 2023 | 1.073 |
| June 30, 2023 | 0.8968 |
| March 31, 2023 | 0.7805 |
| December 31, 2022 | 4.096 |
| September 30, 2022 | 0.0328 |
| June 30, 2022 | 0.5323 |
| March 31, 2022 | 0.4269 |
| December 31, 2021 | 0.0334 |
| September 30, 2021 | 0.018 |
| June 30, 2021 | 0.018 |
| March 31, 2021 | 0.0218 |
| December 31, 2020 | 0.0059 |
| September 30, 2020 | 0.0149 |
| Date | Value |
|---|---|
| June 30, 2020 | |
| March 31, 2020 | 0.0117 |
| January 31, 2020 | |
| October 31, 2019 | |
| July 31, 2019 | |
| April 30, 2019 | |
| January 31, 2019 | 0.00 |
| October 31, 2018 | 0.00 |
| July 31, 2018 | 0.00 |
| April 30, 2018 | 0.0236 |
| January 31, 2018 | 0.00 |
| October 31, 2017 | 0.00 |
| July 31, 2017 | 0.00 |
| April 30, 2017 | 0.00 |
| January 31, 2017 | 0.00 |
| October 31, 2016 | 0.00 |
| July 31, 2016 | 0.00 |
| April 30, 2016 | 0.00 |
| January 31, 2016 | 0.00 |
| October 31, 2015 | 0.00 |
| July 31, 2015 | 0.00 |
| April 30, 2015 | 0.00 |
| January 31, 2015 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| NovelStem International Corp. | -0.8748 |
| Brainstorm Cell Therapeutics, Inc. | -0.1185 |
| Kezar Life Sciences, Inc. | 0.0208 |
| Protara Therapeutics, Inc. | 0.017 |
| Clene, Inc. | -0.9018 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 752.18M |
| Total Liabilities (Quarterly) | 122.20M |
| Shareholders Equity (Quarterly) | 629.98M |
| Current Ratio | 6.958 |
| Net Debt Paydown Yield | -0.02% |